Intermountain Precision Genomics expands DNA-based testing with RxMatch

May 15, 2018

Intermountain Precision Genomics Core Laboratory announced the expansion of RxMatch, a pharmacogenomics service, to all Intermountain Healthcare providers. Originally launched as an antidepressant panel in September 2017, the new RxMatch Comprehensive Panel expands the gene targets from 36 to 97.

Pharmacogenomics is the study of how genes affect a patient’s response to medication.

The new RxMatch Comprehensive Panel includes opioids, statins, immunosuppressants, anti-depressants, and many more. The results, powered by Coriell Life Sciences, seamlessly integrate genomic medicine into clinical care while managing the breadth of information that is obtained through genomic sequencing.

“The objective of this project is to provide the most comprehensive and evidence-based information to the physician, thus decreasing the amount of time and money spent to achieve the correct medication,” said David Loughmiller, laboratory manager for Intermountain Precision Genomics.

“The results are used to guide proper dosage based on a patient’s specific DNA genotype,” said Tom Neuwerth, clinical technology consultant for Intermountain Precision Genomics Lab. “Small genetic variations impact how a patient metabolizes and responds to drugs. Our test helps ordering providers prescribe the right medication, at the right dose, at the right time.”

Patients supply DNA samples using cheek swabs collected by their physicians. Once sample are received, comprehensive reports are available within about a week.

The Independent has the article